Ti Hwei How
Vice President, Oncology AstraZeneca
Seminars
Wednesday 12th November 2025
SERENA-6: ctDNA-Guided Treatment Switch – A Potential New Paradigm in Cancer Management
2:25 pm
- Traditional approach to treating solid tumors uses radiology images to determine clinical progression, to switch treatment to control the disease
- SERENA-6 challenges that paradigm, using ctDNA serial monitoring to detect the emergence of ESR1 mutations in hormone receptor positive metastatic breast cancer (HR+ mBC)
- An early switch to camizestrant plus a CDK4/6 inhibitor upon ctDNA detection of ESR1 mutations during first-line therapy, significantly prolonged progression-free survival (PFS) versus the conventional approach of switching therapy at clinical progression (median PFS 16.0 vs 9.2 months at first interim analysis)
Thursday 13th November 2025
Panel Discussion: Establishing Scalable & Validated Digital Pathology to Support Patient Selection for ADC Therapies
10:30 am
- Establishing robust validity for digital pathology platforms to ensure reproducibility and accuracy across different laboratories
- What is the regulatory pathway for approving digital pathology based CDx approaches in APAC?
- Designing digital pathology networks to address pathologist shortages and ensure equitable diagnostic access in geographically dispersed APAC regions
